RGNX Latest Headlines

Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and RegenXBio (RGNX)

at www.tipranks.com (Mon, 3-Aug 5:30 AM)

REGENXBIO Announces $100 Million Common Stock Offering—What Does This Mean for Investors?

Market Chameleon (Fri, 17-Jul 11:45 AM)

REGENXBIO Targets $100 Million Capital Raise Through Public Offering of Common Stock and Pre-Funded Warrants

Market Chameleon (Fri, 17-Jul 7:31 AM)

REGENXBIO Secures $100 Million Milestone as First Patient Dosed in Key Diabetic Retinopathy Trial

Market Chameleon (Mon, 29-Jun 8:37 AM)

REGENXBIO Advances RGX-202 Toward FDA Approval After Early Completion of Key Duchenne Gene Therapy Study

Market Chameleon (Wed, 24-Jun 9:41 AM)

FDA Streamlines NAVSUNLI Pathway: REGENXBIO Fast-Tracks Potential First Gene Therapy for MPS II

Market Chameleon (Mon, 22-Jun 10:34 AM)

FDA Fast-Tracks REGENXBIO Gene Therapy NAVSUNLI—First Accelerated Approval Pathway for MPS II in Sight

Market Chameleon (Mon, 22-Jun 7:52 AM)

REGENXBIO Highlights Pipeline Progress at Major Investor Conferences—What Should Investors Watch?

Market Chameleon (Tue, 19-May 11:14 AM)

REGENXBIO’s Positive Phase III RGX-202 Data Sets Stage for Duchenne Gene Therapy Push, Yet Cash Burn Raises Questions

Market Chameleon (Thu, 14-May 9:52 AM)

REGENXBIO Achieves Key Milestones in Duchenne and Retinal Gene Therapy Studies, Maintaining Strong Cash Position Into 2027

Market Chameleon (Thu, 14-May 8:18 AM)